On September 24, Viking Therapeutics fell 8.8% in pre-market trading, trading at $38.1 per share, with turnover of $27,900. The decline was triggered by the company's announcement of separate public offerings totaling $400 million, comprising $200 million in common stock and $200 million in convertible senior notes due 2032, with 30-day overallotment options of up to $30 million each.

The financing announcement came immediately after the stock had surged over 34% on September 22 following positive top-line data from its GLP-1/GIP dual agonist VK2735 maintenance study. In that study, participants switching from weekly to biweekly dosing preserved up to 97% of initial weight loss, while those on monthly regimens retained approximately 85%, significantly outperforming placebo at 61%. At the weekly 17.5 mg dose, placebo-adjusted weight reduction reached 22% at week 33.

Net proceeds from the dual offerings will fund clinical development and commercialization of the VK2735 and VK3019 programs. The combination of equity dilution pressure from the dual issuance and profit-taking sentiment following the sharp two-day rally drove the notable pre-market pullback.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with VK2735 as its lead obesity candidate being developed in both injectable and oral formulations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)